Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer

被引:0
|
作者
Conces, Madison L. [1 ]
Mahipal, Amit [1 ]
机构
[1] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland, OH 44106 USA
关键词
rectal cancer; neoadjuvant therapy; chemotherapy; TOTAL MESORECTAL EXCISION; POSTOPERATIVE ADJUVANT CHEMOTHERAPY; COURSE PREOPERATIVE RADIOTHERAPY; CLINICAL COMPLETE RESPONDERS; MEDIAN FOLLOW-UP; QUALITY-OF-LIFE; INTERNATIONAL WATCH; SEXUAL DYSFUNCTION; COLORECTAL-CANCER; RANDOMIZED-TRIAL;
D O I
10.3390/curroncol31010024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Local and metastatic recurrence are primary concerns following the treatment of locally advanced rectal cancer (LARC). Chemoradiation (CRT) can reduce the local recurrence rates and has subsequently moved to the neoadjuvant setting from the adjuvant setting. Pathological complete response (pCR) rates have also been noted to be greater in patients treated with neoadjuvant CRT prior to surgery. The standard approach to treating LARC would often involve CRT followed by surgery and optional adjuvant chemotherapy and remained the treatment paradigm for almost two decades. However, patients were often unable to complete adjuvant chemotherapy due to a decreased tolerance of chemotherapy following surgery, which led to upfront treatment with both CRT and chemotherapy, and total neoadjuvant therapy, or TNT, was created. The efficacy outcomes of local recurrence, disease-free survival, and pCR have improved in patients receiving TNT compared to the standard approach. Additionally, more recent data suggest a possible improvement in overall survival as well. Patients with a complete clinical response following TNT have the opportunity for watch-and-wait surveillance, allowing some patients to undergo organ preservation. Here, we discuss the clinical trials and studies that led to the adoption of TNT as the standard of care for LARC, with the possibility of watch-and-wait surveillance for patients achieving complete responses. We also review the possibility of overtreating some patients with LARC.
引用
收藏
页码:366 / 382
页数:17
相关论文
共 50 条
  • [21] Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Induction or Consolidation Chemotherapy?
    Aref, Amr
    Abdalla, Ahmed
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2515 - +
  • [22] Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management
    Franke, Aaron J.
    Parekh, Hiral
    Starr, Jason S.
    Tan, Sanda A.
    Iqbal, Atif
    George, Thomas J., Jr.
    CLINICAL COLORECTAL CANCER, 2018, 17 (01) : 1 - 12
  • [23] Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial
    Weiser, Martin R.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 1493 - 1495
  • [24] Total neoadjuvant therapy for locally advanced rectal cancer: A western Australian experience
    Oey, Oliver
    Khattak, Adnan
    Ferguson, Tom
    Theophilus, Mary
    Tiong, Siaw Sze
    Ali, Sayed
    Khan, Yasir
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Validation of the Neoadjuvant Rectal Cancer (NAR) Score for Prognostication Following Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
    Shah, Shivani
    Asawa, Palash
    Abel, Stephen
    Wegner, Rodney E.
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (03) : 829 - 836
  • [26] Validation of the Neoadjuvant Rectal Cancer (NAR) Scores for Prognostication Following Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
    Metzger, April
    Abel, Stephen
    Kirichenko, Alexander
    McCormick, James
    Monga, Dulabh
    Wegner, Rodney
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S56 - S56
  • [27] Validation of the Neoadjuvant Rectal Cancer (NAR) Score for Prognostication Following Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
    Shivani Shah
    Palash Asawa
    Stephen Abel
    Rodney E. Wegner
    Journal of Gastrointestinal Cancer, 2023, 54 : 829 - 836
  • [28] Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer
    Zaborowski, A.
    Stakelum, A.
    Winter, D. C.
    BRITISH JOURNAL OF SURGERY, 2019, 106 (08) : 979 - 987
  • [29] Correction to: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial
    Martin R. Weiser
    Annals of Surgical Oncology, 2022, 29 : 3886 - 3886
  • [30] Chemoimmunotherapy in the context of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer
    Shamseddine, A.
    Turfa, R.
    Elias, C.
    Kattan, J.
    Mukherji, D.
    Temraz, S.
    Alqasem, K.
    Amarin, R.
    Al Awabdeh, T.
    Deeba, S.
    Mohamad, I.
    Daoud, F.
    Al Masri, M.
    Dabous, A.
    Hushki, A.
    Jaber, O.
    Charafeddine, M.
    Al Darazi, M.
    Zeidan, Y.
    Geara, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S339 - S339